People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2018 |
| Solve Therapeutics, Inc. | — | Biotechnology | Series C | $162.1M | $255.0M | 2021 |
Langdon Miller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Langdon Miller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 2 | 35 |
| Alan Colowick | 2 | 7 |
| Scott L. Glenn | 1 | 9 |
| Cam Gallagher | 1 | 7 |
| MIN CUI | 1 | 5 |
| Mark Chin | 1 | 4 |
| Peter Colabuono | 1 | 4 |
| Jayson Punwani | 1 | 3 |
| Robert D. Mittendorff | 1 | 2 |
| Karan Takhar | 1 | 2 |
| Jonathan Tobin | 1 | 2 |
| Richard Vincent | 1 | 2 |
| Jayson L. Punwani | 1 | 1 |
| Daniel D. McHugh | 1 | 1 |
| Clayton D. Knox | 1 | 1 |
| Jason Pitts | 1 | 1 |
| Clayton Knox | 1 | 1 |
| Scott Karchmer | 1 | 1 |
| Min L. Cui | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.